Aerts JM - Search Results

1

Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease.

Hollak CE, vom Dahl S, Aerts JM, Belmatoug N, Bembi B, Cohen Y, Collin-Histed T, Deegan P, van Dussen L, Giraldo P, Mengel E, Michelakakis H, Manuel J, Hrebicek M, Parini R, Reinke J, di Rocco M, Pocovi M, Sa Miranda MC, Tylki-Szymanska A, Zimran A, Cox TM. Hollak CE, et al. Among authors: aerts jm. Blood Cells Mol Dis. 2010 Jan 15;44(1):41-7. doi: 10.1016/j.bcmd.2009.09.006. Epub 2009 Oct 4. Blood Cells Mol Dis. 2010. PMID: 19804996

2

The identification of type 1 Gaucher disease patients, asymptomatic cases and carriers in The Netherlands using urine samples: an evaluation.

Aerts JM, Sa Miranda MC, Wanzeller de Lacerda L, van Weely S, Donker-Koopman W, Brouwer-Kelder B, Jansen DC, van Leeuwen M, Schram AW, Tsiapara A, et al. Aerts JM, et al. Clin Chim Acta. 1991 Dec 16;203(2-3):349-61. doi: 10.1016/0009-8981(91)90308-y. Clin Chim Acta. 1991. PMID: 1838035

3

[Gaucher's disease; current developments in the treatment of lysosomal metabolic disease].

Hollak CE, Aerts JM, Goudsmit R. Hollak CE, et al. Among authors: aerts jm. Ned Tijdschr Geneeskd. 1991 Nov 16;135(46):2162-4. Ned Tijdschr Geneeskd. 1991. PMID: 1956441 Review. Dutch. No abstract available.

4

Comparative study on glucocerebrosidase in spleens from patients with Gaucher disease.

Aerts JM, Donker-Koopman WE, Brul S, Van Weely S, Sa Miranda MC, Barranger JA, Tager JM, Schram AW. Aerts JM, et al. Biochem J. 1990 Jul 1;269(1):93-100. doi: 10.1042/bj2690093. Biochem J. 1990. PMID: 2198026 Free PMC article.

5

Conditions affecting the activity of glucocerebrosidase purified from spleens of control subjects and patients with type 1 Gaucher disease.

Aerts JM, Sa Miranda MC, Brouwer-Kelder EM, Van Weely S, Barranger JA, Tager JM. Aerts JM, et al. Biochim Biophys Acta. 1990 Oct 18;1041(1):55-63. doi: 10.1016/0167-4838(90)90122-v. Biochim Biophys Acta. 1990. PMID: 2223847

6

Activity of glucocerebrosidase in extracts of different cell types from type 1 Gaucher disease patients.

Sa Miranda MC, Aerts JM, Pinto R, Fontes A, de Lacerda LW, van Weely S, Barranger J, Tager JM. Sa Miranda MC, et al. Among authors: aerts jm. Clin Genet. 1990 Sep;38(3):218-27. doi: 10.1111/j.1399-0004.1990.tb03573.x. Clin Genet. 1990. PMID: 2225530

7

Individualised low-dose alglucerase therapy for type 1 Gaucher's disease.

Hollak CE, Aerts JM, Goudsmit R, Phoa SS, Ek M, van Weely S, von dem Borne AE, van Oers MH. Hollak CE, et al. Among authors: aerts jm. Lancet. 1995 Jun 10;345(8963):1474-8. doi: 10.1016/s0140-6736(95)91037-9. Lancet. 1995. PMID: 7769902 Clinical Trial.

8

Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.

Hollak CE, van Weely S, van Oers MH, Aerts JM. Hollak CE, et al. Among authors: aerts jm. J Clin Invest. 1994 Mar;93(3):1288-92. doi: 10.1172/JCI117084. J Clin Invest. 1994. PMID: 8132768 Free PMC article.

9

Pathogenesis of lysosomal storage disorders as illustrated by Gaucher disease.

Aerts JM, Van Weely S, Boot R, Hollak CE, Tager JM. Aerts JM, et al. J Inherit Metab Dis. 1993;16(2):288-91. doi: 10.1007/BF00710267. J Inherit Metab Dis. 1993. PMID: 8411983 Review. No abstract available.

10

Role of pH in determining the cell-type-specific residual activity of glucocerebrosidase in type 1 Gaucher disease.

van Weely S, van den Berg M, Barranger JA, Sa Miranda MC, Tager JM, Aerts JM. van Weely S, et al. Among authors: aerts jm. J Clin Invest. 1993 Mar;91(3):1167-75. doi: 10.1172/JCI116276. J Clin Invest. 1993. PMID: 8450045 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

461 results

Search Page

Filters